Lactylation-driven stabilization of the S100A11/ANXA2 complex promotes pancreatic cancer metastasis
Cell Biology and Toxicology · 10.07.2026 · 42 (1)
DOI: 10.1007/s10565-026-10225-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biology and Toxicology, online erschienen am 10.07.2026. Verfasst von Bo Zheng und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Annexin A2, S100 Proteins, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a pronounced Warburg effect and high lactate levels. While lysine lactylation (Kla) is an emerging post-translational modification, its role in regulating the S100A11/ANXA2 complex-a critical driver of membrane repair and metastasis-remains unexplored. In this study, we identified that S100A11 (K3, K55) and ANXA2 (K49) are significantly lactylated in PDAC tissues. Lactate-induced lactylation of S100A11 at K3 and K55 inhibits FBXW11-mediated ubiquitination and proteasomal degradation, thereby stabilizing the protein. This stabilized S100A11 subsequently shields ANXA2 from TRIM21-mediated degradation. Reciprocally, lactylation of ANXA2 at K49 enhances its capacity to recruit S100A11 to the plasma membrane. Functional assays demonstrated that this lactylation-driven interdependent regulatory axis promotes PDAC cell migration, invasion, and metastasis both in vitro and in vivo. Clinical analysis of TCGA data revealed that low expression of both S100A11 and ANXA2 predicts significantly improved progression-free and overall survival in PDAC patients. In summary, our findings establish a novel link between metabolic reprogramming and the post-translational regulation of the membrane repair machinery. Lactylation of the S100A11/ANXA2 axis is a key driver of PDAC progression and serves as a promising prognostic biomarker and potential therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
- Department of Oncology Centre, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
- Department of Oncology Centre, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China. 909690405@qq.com.
- Department of Oncology Centre, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China. 1950999602@qq.com.
Zitieren
APA
Zheng, B., Cai, L., Deng, Y., & Yang, L. (2026). Lactylation-driven stabilization of the S100A11/ANXA2 complex promotes pancreatic cancer metastasis. Cell Biology and Toxicology, 42(1). https://doi.org/10.1007/s10565-026-10225-9
Vancouver
Zheng B, Cai L, Deng Y, Yang L. Lactylation-driven stabilization of the S100A11/ANXA2 complex promotes pancreatic cancer metastasis. Cell Biology and Toxicology. 2026;42(1). doi:10.1007/s10565-026-10225-9
BibTeX
@article{Zheng2026,
author = {Zheng, Bo and Cai, Lijun and Deng, Ying and Yang, Lan},
title = {Lactylation-driven stabilization of the S100A11/ANXA2 complex promotes pancreatic cancer metastasis},
journal = {Cell Biology and Toxicology},
year = {2026},
volume = {42},
number = {1},
doi = {10.1007/s10565-026-10225-9}
}
EUVIMED